Press release
Diabetes Pipeline Insight Report 2023 | Major Companies- Janssen Biotech, Kamada, Adocia, Novo Nordisk, and others
In the Diabetes Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autistic disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Diabetes Pipeline Report
• DelveInsight's Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for diabetes treatment.
• The leading Diabetes Companies include Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others
• Promising Diabetes Pipeline Therapies include Enavogliflozin, Golimumab, Dasiglucagon, ThermoStem, rGDF11, IMCY-0098, Insulin icodec, CagriSema, FDC Sema-OW GIP, SemaDapa FDC, ENT-001, AG019, JTT-662, AVT-001, AZD-0186, Cotadutide, LABP-111, VX-880, Encapsulated islet cell program, CPP-1X-T, REMD-477, AT-1501, LY 3209590, Orforglipron, LY3437943, Mazdutide, Peptide YY analogue agonist, GIPR agonist long acting, GIPR Agonist Long Acting II, LY 3493269, NNC0363-0845, Diamyd, ProTrans, VC-02, OPT101, Ladarixin, ILT-101, Stem Cell Educator Therapy, ORMD-0801, Golimumab, JAG301, SQZ TAC research program, VCTX 211, and others.
• The Diabetes Companies and academics are working to assess challenges and seek opportunities that could influence Diabetes R&D. The therapies under development are focused on novel approaches for Diabetes.
Request a sample and discover the recent advances in Diabetes Drug Treatment @ Diabetes Pipeline Report- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Diabetes Overview
Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or alternatively, when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas.
Recent Developmental Activities in the Diabetes Treatment Landscape
• In February 2023, Genprex, Inc. announced that data highlighting the potential of its gene therapy for Type 1 diabetes was being presented by its research collaborators at the University of Pittsburgh at the four-day International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023).These results were compelling as they demonstrated the potential for this gene therapy to create newly formed beta-like cells that can produce insulin. They also validated earlier studies of this approach in diabetic mouse models that showed restoration of normal blood glucose levels for several months.
• In February 2023, Provention Bio, Inc. announced the closing of the $35 million equity investment from Sanofi US under the previously announced Co-Promotion Agreement and Securities Purchase Agreement (the "Purchase Agreement").Pursuant to the Purchase Agreement, Sanofi purchased 2,712,497 shares of the Company's common stock, par value $0.0001 per share, at a price of $12.90 per share, representing a total investment of $35 million.
• In January 2023, iTolerance, Inc. announced it has entered into a Master Services Agreement (MSA) with the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine, for the advancement of its novel iTOL-100 platform technology as a potential cure for Type 1 Diabetes.
• In November 2022, Biocon Limited announced the signing of a semi-exclusive partnership agreement with Zentiva, a leading pharmaceutical company in Europe, for the commercialization of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity.Under the terms of this agreement, Biocon is responsible for the manufacturing and supply of Liraglutide to Zentiva for its commercialization across 30 countries in Europe. Biocon also retained the right to commercialize this product under its own brand in the region.
• In November 2022, The US Food and Drug Administration (FDA) approved Provention Bio's biologics license application (BLA) for Tzield (teplizumab-mzwv) to treat type 1 diabetes (T1D) patients. The anti-CD3-directed antibody Tzield aims to delay the onset of Stage 3 T1D in adults and children aged eight years and above who are currently with stage 2 T1D.
Find out more information of the latest Drugs Launch, News, and Breakthroughs of the Diabetes Pipeline Report @ Latest Diabetes Drugs Launch- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Diabetes Emerging Drugs Profile
• Enavogliflozin - Daewoong
Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.
• Golimumab - Janssen Biotech
Golimumab is a human IgG1 monoclonal antibody, derived from immunizing genetically engineered mice with human TNFα. It inhibits soluble and transmembrane forms of TNF-α by binding to their specific receptors and blocking in consequence their bioactivity. It is currently under Phase II development for the treatment of Type 1 diabetes mellitus.
Diabetes Pipeline Therapeutics Assessment
There are approx. 200+ key companies which are developing the therapies for Diabetes. The companies which have their Diabetes drug candidates in the most advanced stage, i.e. phase III include, Daewoong.
Learn more about the emerging Diabetes Pipeline Therapies @ Diabetes Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Diabetes Pipeline Report
• Coverage- Global
• Diabetes Companies- Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others
• Diabetes Pipeline Therapies- Enavogliflozin, Golimumab, Dasiglucagon, ThermoStem, rGDF11, IMCY-0098, Insulin icodec, CagriSema, FDC Sema-OW GIP, SemaDapa FDC, ENT-001, AG019, JTT-662, AVT-001, AZD-0186, Cotadutide, LABP-111, VX-880, Encapsulated islet cell program, CPP-1X-T, REMD-477, AT-1501, LY 3209590, Orforglipron, LY3437943, Mazdutide, Peptide YY analogue agonist, GIPR agonist long acting, GIPR Agonist Long Acting II, LY 3493269, NNC0363-0845, Diamyd, ProTrans, VC-02, OPT101, Ladarixin, ILT-101, Stem Cell Educator Therapy, ORMD-0801, Golimumab, JAG301, SQZ TAC research program, VCTX 211, and others
• Diabetes Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Dive deep into rich insights for drugs for Diabetes Market Drivers and Diabetes Market Barriers, click here @ Diabetes Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Diabetes: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetes - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Diabetes Collaboration Deals
9. Late Stage Products (Phase III)
10. Enavogliflozin: Daewoong
11. Mid Stage Products (Phase II)
12. Golimumab: Janssen Biotech
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase II/I)
15. IMCY-0098: ImCyse
16. Drug profiles in the detailed report…..
17. Pre-clinical and Discovery Stage Products
18. ENT-001: Enthera
19. Drug profiles in the detailed report…..
20. Inactive Products
21. Diabetes Key Companies
22. Diabetes Key Products
23. Diabetes- Unmet Needs
24. Diabetes- Market Drivers and Barriers
25. Diabetes- Future Perspectives and Conclusion
26. Diabetes Analyst Views
27. Diabetes Key Companies
28. Appendix
Got Queries? Find out the related information on Diabetes Mergers and acquisitions, Diabetes Licensing Activities @ Diabetes Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetes Pipeline Insight Report 2023 | Major Companies- Janssen Biotech, Kamada, Adocia, Novo Nordisk, and others here
News-ID: 3005728 • Views: …
More Releases from DelveInsight Business Research
Antibody-Drug Conjugates (ADCs) in Oncology Competitive Landscape: DelveInsight …
A comprehensive deep dive into one of oncology's fastest-expanding therapeutic classes covering pipelines, clinical advancements, strategic collaborations, and future-market perspectives
DelveInsight, a prominent market research and strategic consulting company specializing in the life sciences industry, has unveiled its latest intelligence offering, "Antibody-Drug Conjugates (ADCs) - Competitive Landscape, 2025." This extensive report provides a panoramic view of the global ADC space, including detailed evaluations of more than 200 biopharmaceutical companies and 220+…
Atopic Dermatitis Pipeline 2025: FDA Approvals and Clinical Trials Landscape wit …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Atopic Dermatitis pipeline constitutes 100+ key companies continuously working towards developing 120+ Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Ankylosing Spondylitis Pipeline 2025: Therapies, MOA Insights, and Key Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ankylosing Spondylitis pipeline constitutes 20+ key companies continuously working towards developing 20+ Ankylosing Spondylitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Ankylosing Spondylitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Diabetic Foot Ulcers Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Foot Ulcers pipeline constitutes 20+ key companies continuously working towards developing 25+ Diabetic Foot Ulcers treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The…
More Releases for Diabetes
Major Force in the Diabetes Pen Market 2025: Diabetes Fuels Surge In Demand For …
How Will the Diabetes Pen Market Grow, and What Is the Projected Market Size?
The diabetes pen market is projected to grow from $29.24 billion in 2024 to $31.22 billion in 2025, at a CAGR of 6.8%. Growth is fueled by the rising need for managing diabetes, advancements in diabetes care, and an increasing focus on patient-friendly medication administration tools.
The diabetes pen market is projected to grow strongly, reaching $40.17 billion…
Diabetes Monitoring Devices Market: Regaining Its Glory| Ascensia Diabetes Care, …
The Latest Study Published by HTF MI Research on the "Diabetes Monitoring Devices Market'' evaluates market size, trend and forecast to 2029. The Diabetes Monitoring Devices market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges…
Prevalence of Diabetes Drives Opportunities for Type-2 Diabetes Market
The Type-2 Diabetes Market Analysis, 2023, by MarkNtel Advisors, presents a well-researched, detail-driven, and accurate study for the stakeholders. This analysis entails prominent aspects like trends, & recent developments, drivers, opportunities, challenges, & restraints, among other parameters, influencing the overall industry expansion across different locations. This report comprises data from historic years (2018-21) & the base year (2022) to put together an estimation of the forecast period (2023-28).
According to Type-2 Diabetes Market…
Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face.
Dr. Marlene Merritt (from the Merritt Wellness Center in…
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system.
As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important.
The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end…
Self-Monitoring Blood Glucose Devices Market Study by Advance Application [Type …
The global self-monitoring blood glucose devices market was valued at $7,768 million in 2017 and is projected to reach $10,828 million by 2025 at a CAGR of 4.2% from 2018 to 2025. Monitoring of blood glucose is an essential step in diabetes management. Blood glucose monitoring devices are predominantly used to monitor a patient’s blood glucose level. Self-monitoring blood glucose (SMBG) devices are easy-to-use and enable people to monitor their…
